(Reuters) -Amgen said on Monday its experimental cancer therapy significantly improved overall survival in patients with advanced gastric cancer when combined with chemotherapy, marking a potential breakthrough for one of the deadliest cancers.
Patients receiving the therapy, bemarituzumab, along with chemotherapy in the late-stage trial lived longer than those who received chemotherapy alone, the company said.
The drug targets a protein called FGFR2b, which is overexpressed in about 16% of patients with advanced gastric cancer, Amgen added.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Shreya Biswas)
